Compare URBN & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | URBN | RYTM |
|---|---|---|
| Founded | 1970 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 6.4B |
| IPO Year | 1993 | 2017 |
| Metric | URBN | RYTM |
|---|---|---|
| Price | $81.69 | $113.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $86.00 | ★ $125.77 |
| AVG Volume (30 Days) | ★ 2.9M | 887.7K |
| Earning Date | 11-25-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.24 | N/A |
| EPS | ★ 5.28 | N/A |
| Revenue | ★ $5,999,726,000.00 | $174,334,000.00 |
| Revenue This Year | $11.95 | $47.34 |
| Revenue Next Year | $7.63 | $57.18 |
| P/E Ratio | $15.50 | ★ N/A |
| Revenue Growth | 11.09 | ★ 54.92 |
| 52 Week Low | $41.89 | $45.91 |
| 52 Week High | $83.38 | $122.20 |
| Indicator | URBN | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 68.91 | 59.90 |
| Support Level | $73.66 | $99.96 |
| Resistance Level | $79.92 | $122.20 |
| Average True Range (ATR) | 3.42 | 5.28 |
| MACD | 1.01 | 1.05 |
| Stochastic Oscillator | 92.22 | 61.92 |
Founded in 1970, Philadelphia-based Urban Outfitters is an apparel and home goods retailer that operates more than 700 stores and e-commerce in the United States, which accounts for about 87% of sales, and other regions. Its retail nameplates are Urban Outfitters (23% of fiscal 2025 sales), Free People/Movement (26%), and Anthropologie (44%). Retail accounted for 88% of fiscal 2025 revenue, but Urban Outfitters also sells products through a wholesale operation, owns some restaurants, and operates a fast-growing clothing rental and resale business called Nuuly (7% of sales). Urban Outfitters primarily markets to young adults and offers products in categories such as apparel (66% of sales), home goods (16% of sales), accessories (13% of sales), and more.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.